The costs of care for patients with chronic kidney disease (CKD) rise rapidly—even in the early stages of the disease, according to new research.
About 26 million US adults have CKD (Coresh J, et al. JAMA 2007; 298:2038–2047). Patients who progress to end stage renal disease (ERSD) require expensive care, which currently accounts for as much as 6% of Medicare spending despite such patients only making up 1% of the Medicare population. To reduce such spending, efforts to slow progression of the earlier stages of CKD have been proposed. But the costs of CKD at various stages, and